Hematopoietic Cell Transplantation in Hematological Malignancies: Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Publication date: Available online 20 June 2017
Source:Hematology/Oncology and Stem Cell Therapy
Author(s): Adetola Kassim, Bipin N. Savani
Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and improvements in survival. Recent era has witnessed an explosive information about the molecular pathophysiology of AML. By early identification of patients at a high risk of relapse, it is expected that a majority of eligible patients will receive HCT in first complete remission. Novel conditioning regimens have been explored to improve transplant outcomes in AML. Currently, a stem cell source can be found for virtually all patients who have an indication to receive HCT. The area of investigation will likely continue to be of interest in terms of optimizing transplant outcomes.



http://ift.tt/2sVDYF1